Publication

To Bridge or Not to Bridge: Modelling Periprocedural Anticoagulation Management

van der Pol, S., Jacobs, M., Meijer, K., Piersma-Wichers, M. G., Tieleman, RG., Postma, M. & van Hulst, M., 3-Aug-2018, p. E417. 1 p.

Research output: Contribution to conferencePosterAcademic

Copy link to clipboard

Documents

DOI

Purpose: For atrial fibrillation (AF) patients receiving vitamin K antagonists (VKAs), careful management of anticoagulation is important around surgical procedures to minimize the stroke and bleeding risks. If the VKA needs to be stopped periprocedurally to reduce the risk of bleeding, a decision needs to be made whether to bridge this period with a low-molecular weight heparin (LMWH). We aimed to develop a model to compare two periprocedural strategies for AF patients that have to interrupt VKA treatment: administering a LMWH or forgoing bridging therapy.
Method(s): A probabilistic Markov model was developed to simulate both a bridge and a non-bridge cohort of AF patients periprocedurally. Modelled events were based on the clinically used CHA2DS2-VASc and HAS-BLED stroke and bleeding prediction rules. To predict strokes, INR values were considered. Quality-adjusted life expectancy, based on the beforementioned clinical endpoints, was the main outcome considered.

Result(s): The base case analysis shows that bridging anticoagulation increases the bleeding rate, but reduces the stroke rate. Bridging may be beneficial for patients with a CHA2DS2-VASc scores of 6 or higher and HAS-BLED scores of 0 to 2. For expected shorter periods to reach therapeutic INR, bridging therapy is less likely to be beneficial.

Conclusion(s): For patients at high risk of bleeding, bridging anticoagulation Is not likely to be beneficial. For patients at high risk of stroke and low risk of bleeding, bridging anticoagulation may result in additional quality adjusted life years. INR management is an important factor to consider periprocedurally when making the decision whether to bridge.
Original languageEnglish
PagesE417
Number of pages1
Publication statusPublished - 3-Aug-2018
Event17th Biennial European Meeting of the Society for Medical Decision Making - Leiden, Netherlands
Duration: 10-Jun-201812-Jun-2018
https://smdm.confex.com/smdm/17bec/meetingapp.cgi/Home/0

Conference

Conference17th Biennial European Meeting of the Society for Medical Decision Making
CountryNetherlands
CityLeiden
Period10/06/201812/06/2018
Internet address

Event

17th Biennial European Meeting of the Society for Medical Decision Making

10/06/201812/06/2018

Leiden, Netherlands

Event: Conference

Related Publications
  1. Perioperative Bridging of Vitamin K Antagonist Treatment in Patients with Atrial Fibrillation: Only a Very Small Group of Patients Benefits

    van der Pol, S., Jacobs, M. S., Meijer, K., Piersma-Wichers, M. G., Tieleman, R. G., Postma, M. J. & van Hulst, M., 1-May-2019, In : Europace. 21, 5, p. 716–723 8 p., 308.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (1) »

View graph of relations

Download statistics

No data available

ID: 80486941